Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06190886 · ClinicalTrials.gov registry record · Phase 1
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
A Phase 1 study of Solid Tumor and Advanced Cancer, sponsored by Proviva Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 3
- Study locations
NCT06190886 is a Phase 1 study of Solid Tumor and Advanced Cancer that is actively recruiting participants, run by Proviva Therapeutics. The registered enrollment target is 26 participants, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06190886, a Phase 1 study of Solid Tumor and Advanced Cancer, is actively recruiting participants, sponsored by Proviva Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of PTX-912 in patients with locally advanced or metastatic solid tumors. To evaluate the PK and immunogenicity profile of PTX-912. To evaluate the preliminary anti-tumor activity of PTX-912. Participants will be treated with PTX-912 via iv infusion, every 2 weeks until progression of disease, unacceptable toxicity, or 12 months of total study therapy.
Conditions Studied
Interventions
- DRUG PTX-912
Study Locations (3)
California
- City of Hope National Medical Center - Duarte
Florida
- University of Miami - Miami
Nebraska
- Nebraska Cancer Specialists (NCS) - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2024-06-11 |
| Est. Completion | 2026-07-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06190886
The ClinicalTrials.gov registry entry for NCT06190886 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (88% lower). The listed sponsor is Proviva Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which PTX-912 is the first listed.
NCT06190886 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Nebraska.
Frequently Asked Questions
What is clinical trial NCT06190886 about?
NCT06190886 is a clinical study titled "A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors". The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of PTX-912 in patients with locally advanced or metastatic solid tumors. To evaluate the PK and immunogenicity profile of PTX-912. To evaluate the preliminary anti-tumor activity of PTX-912. Participants ...
What is the current status of trial NCT06190886?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2024-06-11. Estimated completion is 2026-07-24.
What conditions does trial NCT06190886 study?
This clinical trial studies the following conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer.
What interventions are being tested in trial NCT06190886?
The interventions under investigation include: PTX-912 (DRUG).
Who is sponsoring clinical trial NCT06190886?
This trial is sponsored by Proviva Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06190886 being conducted?
This trial has 3 study locations across California, Florida, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.